Analysts Set InflaRx N.V. (NASDAQ:IFRX) PT at $7.50

Shares of InflaRx N.V. (NASDAQ:IFRX) have earned an average recommendation of “Moderate Buy” from the seven analysts that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $7.50.

A number of analysts have recently issued reports on IFRX shares. Raymond James Financial reiterated an “outperform” rating on shares of InflaRx in a report on Wednesday, December 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of InflaRx in a research note on Monday, December 29th. Wall Street Zen lowered shares of InflaRx from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Leerink Partners restated a “market perform” rating and set a $2.00 target price (down previously from $5.00) on shares of InflaRx in a report on Wednesday, December 3rd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $6.00 price target on shares of InflaRx in a research report on Tuesday, December 30th.

InflaRx Stock Down 4.2%

IFRX stock opened at $0.86 on Thursday. The company has a market cap of $57.57 million, a price-to-earnings ratio of -1.26 and a beta of 1.46. The business has a fifty day simple moving average of $1.02 and a 200-day simple moving average of $1.16. InflaRx has a 52 week low of $0.71 and a 52 week high of $2.77.

InflaRx (NASDAQ:IFRX) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.16) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.16). The firm had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $0.03 million. As a group, analysts expect that InflaRx will post -1.04 earnings per share for the current fiscal year.

Institutional Investors Weigh In On InflaRx

Several hedge funds have recently modified their holdings of the stock. Cubist Systematic Strategies LLC boosted its holdings in InflaRx by 33.9% in the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock worth $31,000 after acquiring an additional 7,616 shares during the period. Concurrent Investment Advisors LLC lifted its position in shares of InflaRx by 56.9% during the fourth quarter. Concurrent Investment Advisors LLC now owns 52,951 shares of the company’s stock worth $53,000 after purchasing an additional 19,200 shares in the last quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of InflaRx by 158.3% in the second quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,000 shares of the company’s stock valued at $118,000 after purchasing an additional 91,927 shares during the period. Susquehanna International Group LLP acquired a new stake in InflaRx during the 3rd quarter valued at $190,000. Finally, ADAR1 Capital Management LLC purchased a new stake in InflaRx during the 3rd quarter worth $214,000. 42.39% of the stock is currently owned by hedge funds and other institutional investors.

About InflaRx

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.